Skip to content

Study · Observational study · n = 3,022 · 2024

12 results

Safety and Effectiveness of Dulaglutide in the Treatment of Type 2 Diabetes Mellitus: A Korean Real-World Post-Marketing Study.

Han J, Lee WJ, Hur KY, Cho JH, Lee BW, Park CY

Diabetes & metabolism journal2 Feb 2024Cited by 5 (Europe PMC)

PMID38310883 (opens in a new tab)PMCIDPMC11140407 (opens in a new tab)DOI10.4093/dmj.2023.0030 (opens in a new tab)PepBankPUB-38310883
Read at sourcePubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

  1. 01HumanObservational studySafety outcome

    In Korean adults with T2DM receiving dulaglutide, 819 adverse events were reported.

    In plain wordsKorean adults with T2DM receiving dulaglutide reported 819 adverse events.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableAdverse events
    Study

    n = 3,022

    Analysis
    Primary
    Outcome group
    Adverse events · Whole body
    Studied dose
    0.75 or 1.5 mgAs given in this study (human).

    Measurements

    Adverse events
    819 events
    Safety analysis set

    Source sentences

    Summary
    The number of adverse events reported was 819; of these, 68 (8.3%) were serious adverse events.
    3 context sentences
    Summary · context
    Data were collected from 3,067 subjects, and 3,022 subjects who received ≥1 dose (of any strength) of dulaglutide were included in the safety analysis set (53% female, mean age 56 years; diabetes duration 11.2 years, mean HbA1c 8.8%).
    Summary · context
    This was a real-world, prospective, non-interventional post-marketing safety study conducted from May 26, 2015 to May 25, 2021 at 85 Korean healthcare centers using electronic case data.
    Summary · context
    Data on patients using dulaglutide 0.75 mg/0.5 mL or the dulaglutide 1.5 mg/0.5 mL single-use pens were collected and pooled.
  2. 02HumanObservational studySafety outcome

    In Korean adults with T2DM receiving dulaglutide, 68 adverse events were serious, representing 8.3% of events.

    In plain wordsIn Korean adults with T2DM receiving dulaglutide, 68 adverse events were serious.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableSerious adverse events
    Study

    n = 3,022

    Analysis
    Primary
    Outcome group
    Adverse events · Whole body
    Studied dose
    0.75 or 1.5 mgAs given in this study (human).

    Measurements

    Serious adverse events
    68 events
    Dulaglutide
    Serious share of adverse events
    8.3%
    All adverse events

    Source sentences

    Summary
    The number of adverse events reported was 819; of these, 68 (8.3%) were serious adverse events.
    2 context sentences
    Summary · context
    This was a real-world, prospective, non-interventional post-marketing safety study conducted from May 26, 2015 to May 25, 2021 at 85 Korean healthcare centers using electronic case data.
    Summary · context
    Data on patients using dulaglutide 0.75 mg/0.5 mL or the dulaglutide 1.5 mg/0.5 mL single-use pens were collected and pooled.
  3. 03HumanObservational studySafety outcome

    One death was reported among Korean adults with T2DM receiving dulaglutide.

    In plain wordsOne death was reported among Korean adults with T2DM receiving dulaglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableDeath
    Study

    n = 3,022

    Analysis
    Primary
    Outcome group
    Mortality · Whole body
    Studied dose
    0.75 or 1.5 mgAs given in this study (human).

    Measurements

    Deaths
    1 deaths
    Safety analysis set

    Source sentences

    Summary
    One death was reported.
    2 context sentences
    Summary · context
    This was a real-world, prospective, non-interventional post-marketing safety study conducted from May 26, 2015 to May 25, 2021 at 85 Korean healthcare centers using electronic case data.
    Summary · context
    Data on patients using dulaglutide 0.75 mg/0.5 mL or the dulaglutide 1.5 mg/0.5 mL single-use pens were collected and pooled.
  4. 04HumanObservational studySafety outcome

    In Korean adults with T2DM receiving dulaglutide, adverse events were mostly mild.

    In plain wordsAdverse events were mostly mild in Korean adults with T2DM receiving dulaglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableAdverse event severity
    Study

    n = 3,022

    Analysis
    Primary
    Outcome group
    Adverse events · Whole body
    Studied dose
    0.75 or 1.5 mgAs given in this study (human).

    Source sentences

    Summary
    Adverse events were mostly mild in severity;
    2 context sentences
    Summary · context
    This was a real-world, prospective, non-interventional post-marketing safety study conducted from May 26, 2015 to May 25, 2021 at 85 Korean healthcare centers using electronic case data.
    Summary · context
    Data on patients using dulaglutide 0.75 mg/0.5 mL or the dulaglutide 1.5 mg/0.5 mL single-use pens were collected and pooled.
  5. 05HumanObservational studySafety outcome

    In Korean adults with T2DM, 60.81% of reported adverse events were considered related to dulaglutide.

    In plain wordsIn Korean adults with T2DM, 60.81% of reported adverse events were considered related to dulaglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableDrug-related adverse events
    Study

    n = 3,022

    Analysis
    Primary
    Outcome group
    Adverse events · Whole body
    Studied dose
    0.75 or 1.5 mgAs given in this study (human).

    Measurements

    Related adverse events
    60.81%
    All adverse events

    Source sentences

    Summary
    60.81% of adverse events were considered related to dulaglutide.
    2 context sentences
    Summary · context
    This was a real-world, prospective, non-interventional post-marketing safety study conducted from May 26, 2015 to May 25, 2021 at 85 Korean healthcare centers using electronic case data.
    Summary · context
    Data on patients using dulaglutide 0.75 mg/0.5 mL or the dulaglutide 1.5 mg/0.5 mL single-use pens were collected and pooled.
  6. 06HumanObservational studyEfficacy outcome

    In Korean adults with T2DM, dulaglutide was linked to a significant HbA1c reduction from baseline at 12 weeks.

    In plain wordsIn Korean adults with T2DM, dulaglutide was linked to lower HbA1c than at baseline after 12 weeks.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHbA1c at early follow-up
    Study

    n: not reported in source

    Comparator
    Baseline
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.75 or 1.5 mg · 12 weeksAs given in this study (human).

    Measurements

    HbA1c reduction
    0.96%
    12 weeks versus baseline

    Source sentences

    Summary
    At 12/24 weeks there were significant (P<0.0001) reductions from baseline in least-squares mean HbA1c (0.96%/0.95%), fasting blood glucose (26.24/24.43 mg/dL), and body weight (0.75/1.21 kg).
    2 context sentences
    Summary · context
    This was a real-world, prospective, non-interventional post-marketing safety study conducted from May 26, 2015 to May 25, 2021 at 85 Korean healthcare centers using electronic case data.
    Summary · context
    Data on patients using dulaglutide 0.75 mg/0.5 mL or the dulaglutide 1.5 mg/0.5 mL single-use pens were collected and pooled.
  7. 07HumanObservational studyEfficacy outcome

    In Korean adults with T2DM, dulaglutide was linked to a significant HbA1c reduction from baseline at 24 weeks.

    In plain wordsIn Korean adults with T2DM, dulaglutide was linked to lower HbA1c than at baseline after 24 weeks.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHbA1c at later follow-up
    Study

    n: not reported in source

    Comparator
    Baseline
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.75 or 1.5 mg · 24 weeksAs given in this study (human).

    Measurements

    HbA1c reduction
    0.95%
    24 weeks versus baseline

    Source sentences

    Summary
    At 12/24 weeks there were significant (P<0.0001) reductions from baseline in least-squares mean HbA1c (0.96%/0.95%), fasting blood glucose (26.24/24.43 mg/dL), and body weight (0.75/1.21 kg).
    2 context sentences
    Summary · context
    This was a real-world, prospective, non-interventional post-marketing safety study conducted from May 26, 2015 to May 25, 2021 at 85 Korean healthcare centers using electronic case data.
    Summary · context
    Data on patients using dulaglutide 0.75 mg/0.5 mL or the dulaglutide 1.5 mg/0.5 mL single-use pens were collected and pooled.
  8. 08HumanObservational studyEfficacy outcome

    In Korean adults with T2DM, dulaglutide was linked to significantly lower fasting glucose than baseline at 12 weeks.

    In plain wordsIn Korean adults with T2DM, dulaglutide was linked to lower fasting glucose than at baseline after 12 weeks.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseFasting glucose at early follow-up
    Study

    n: not reported in source

    Comparator
    Baseline
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.75 or 1.5 mg · 12 weeksAs given in this study (human).

    Measurements

    Fasting glucose reduction
    26.24 mg/dL
    12 weeks versus baseline

    Source sentences

    Summary
    At 12/24 weeks there were significant (P<0.0001) reductions from baseline in least-squares mean HbA1c (0.96%/0.95%), fasting blood glucose (26.24/24.43 mg/dL), and body weight (0.75/1.21 kg).
    2 context sentences
    Summary · context
    This was a real-world, prospective, non-interventional post-marketing safety study conducted from May 26, 2015 to May 25, 2021 at 85 Korean healthcare centers using electronic case data.
    Summary · context
    Data on patients using dulaglutide 0.75 mg/0.5 mL or the dulaglutide 1.5 mg/0.5 mL single-use pens were collected and pooled.
  9. 09HumanObservational studyEfficacy outcome

    In Korean adults with T2DM, dulaglutide was linked to significantly lower fasting glucose than baseline at 24 weeks.

    In plain wordsIn Korean adults with T2DM, dulaglutide was linked to lower fasting glucose than at baseline after 24 weeks.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseFasting glucose at later follow-up
    Study

    n: not reported in source

    Comparator
    Baseline
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.75 or 1.5 mg · 24 weeksAs given in this study (human).

    Measurements

    Fasting glucose reduction
    24.43 mg/dL
    24 weeks versus baseline

    Source sentences

    Summary
    At 12/24 weeks there were significant (P<0.0001) reductions from baseline in least-squares mean HbA1c (0.96%/0.95%), fasting blood glucose (26.24/24.43 mg/dL), and body weight (0.75/1.21 kg).
    2 context sentences
    Summary · context
    This was a real-world, prospective, non-interventional post-marketing safety study conducted from May 26, 2015 to May 25, 2021 at 85 Korean healthcare centers using electronic case data.
    Summary · context
    Data on patients using dulaglutide 0.75 mg/0.5 mL or the dulaglutide 1.5 mg/0.5 mL single-use pens were collected and pooled.
  10. 10HumanObservational studyEfficacy outcome

    In Korean adults with T2DM, dulaglutide was linked to significantly lower weight than baseline at 12 weeks.

    In plain wordsIn Korean adults with T2DM, dulaglutide was linked to lower weight than at baseline after 12 weeks.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseWeight at early follow-up
    Study

    n: not reported in source

    Comparator
    Baseline
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.75 or 1.5 mg · 12 weeksAs given in this study (human).

    Measurements

    Weight reduction
    0.75 kg
    12 weeks versus baseline

    Source sentences

    Summary
    At 12/24 weeks there were significant (P<0.0001) reductions from baseline in least-squares mean HbA1c (0.96%/0.95%), fasting blood glucose (26.24/24.43 mg/dL), and body weight (0.75/1.21 kg).
    2 context sentences
    Summary · context
    This was a real-world, prospective, non-interventional post-marketing safety study conducted from May 26, 2015 to May 25, 2021 at 85 Korean healthcare centers using electronic case data.
    Summary · context
    Data on patients using dulaglutide 0.75 mg/0.5 mL or the dulaglutide 1.5 mg/0.5 mL single-use pens were collected and pooled.
  11. 11HumanObservational studyEfficacy outcome

    In Korean adults with T2DM, dulaglutide was linked to significantly lower weight than baseline at 24 weeks.

    In plain wordsIn Korean adults with T2DM, dulaglutide was linked to lower weight than at baseline after 24 weeks.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseWeight at later follow-up
    Study

    n: not reported in source

    Comparator
    Baseline
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.75 or 1.5 mg · 24 weeksAs given in this study (human).

    Measurements

    Weight reduction
    1.21 kg
    24 weeks versus baseline

    Source sentences

    Summary
    At 12/24 weeks there were significant (P<0.0001) reductions from baseline in least-squares mean HbA1c (0.96%/0.95%), fasting blood glucose (26.24/24.43 mg/dL), and body weight (0.75/1.21 kg).
    2 context sentences
    Summary · context
    This was a real-world, prospective, non-interventional post-marketing safety study conducted from May 26, 2015 to May 25, 2021 at 85 Korean healthcare centers using electronic case data.
    Summary · context
    Data on patients using dulaglutide 0.75 mg/0.5 mL or the dulaglutide 1.5 mg/0.5 mL single-use pens were collected and pooled.
  12. 12HumanObservational studyOther

    In Korean adults with T2DM receiving dulaglutide, 72.73% completed the study.

    In plain wordsIn Korean adults with T2DM receiving dulaglutide, 72.73% completed the study.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableStudy completion
    Study

    n = 3,022

    Outcome group
    Treatment adherence and retention · Whole body
    Studied dose
    0.75 or 1.5 mgAs given in this study (human).

    Measurements

    Study completion
    72.73%
    Safety analysis set

    Source sentences

    Summary
    This study was completed by 72.73% (2,198/3,022) of subjects.
    2 context sentences
    Summary · context
    This was a real-world, prospective, non-interventional post-marketing safety study conducted from May 26, 2015 to May 25, 2021 at 85 Korean healthcare centers using electronic case data.
    Summary · context
    Data on patients using dulaglutide 0.75 mg/0.5 mL or the dulaglutide 1.5 mg/0.5 mL single-use pens were collected and pooled.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.